Selenoprotein N and SEPN1-Related Myopathies: Mechanisms, Models, and Therapeutic Perspectives
Biomolecules · 2026
DOI: 10.3390/biom16010125 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomolecules, 2026. Verfasst von Martina Lanza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, University of Salento, 73100 Lecce, Italy. Hauptthemen laut MEDLINE: Selenoproteins, Muscular Diseases, Muscle Proteins. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP), Ministry of University and Research, National Recovery and Resilience Plan.
Abstract (Originalsprache)
Selenoprotein N (SelN or SELENON) is a selenium-containing protein of the endoplasmic/sarcoplasmic reticulum (ER/SR), encoded by the SEPN1 gene. In skeletal muscle, SelN is particularly important for regulating SR calcium homeostasis. It acts as a calcium sensor, modulating the activity of the sarcoplasmic reticulum calcium pump (SERCA) through a redox-dependent mechanism. Loss-of-function mutations in the SEPN1 gene give rise to a spectrum of skeletal muscle disorders collectively referred to as SEPN1-related myopathies (SEPN1-RM). Histopathologically, SEPN1-RM is characterized by the presence of minicores, which are localized regions within muscle fibers exhibiting mitochondrial depletion (i.e., cores) and sarcomeric disarray. As no effective therapy is currently available for SEPN1-RM, understanding SelN biology through loss-of-function models remains essential for elucidating disease mechanisms and identifying potential therapeutic targets. This review examines the current knowledge on SelN function and the pathological mechanisms underlying SEPN1 loss-of-function, with a particular focus on the connection between calcium handling, oxidative/ER stress, and muscle dysfunction. It also highlights emerging strategies aimed at restoring SelN activity or mitigating downstream defects, outlining potential therapeutic avenues for SEPN1-RM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Medicine, University of Salento, 73100 Lecce, Italy.
- Istituto di Ricerche Farmacologiche Mario Negri IRCCS, 20156 Milan, Italy.
- Department of Biomolecular Sciences, University of Urbino Carlo Bo, 61029 Urbino, Italy.
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", 70125 Bari, Italy.
ORCID-Profile: Ester Zito, Giorgia Dinoi, Annamaria De Luca, Paola Imbrici, Antonella Liantonio, Elena Conte
Förderung
- Ministry of University and Research (MUR), National Recovery and Resilience Plan (NRRP)
- Ministry of University and Research
- National Recovery and Resilience Plan
Zitieren
APA
Lanza, M., Zito, E., Dinoi, G., Buono, A. V., De Luca, A., Imbrici, P., Liantonio, A., & Conte, E. (2026). Selenoprotein N and SEPN1-Related Myopathies: Mechanisms, Models, and Therapeutic Perspectives. Biomolecules. https://doi.org/10.3390/biom16010125
Vancouver
Lanza M, Zito E, Dinoi G, Buono AV, De Luca A, Imbrici P, et al. Selenoprotein N and SEPN1-Related Myopathies: Mechanisms, Models, and Therapeutic Perspectives. Biomolecules. 2026. doi:10.3390/biom16010125
BibTeX
@article{Lanza2026,
author = {Lanza, Martina and Zito, Ester and Dinoi, Giorgia and Buono, Antonio Vittorio and De Luca, Annamaria and Imbrici, Paola and Liantonio, Antonella and Conte, Elena},
title = {Selenoprotein N and SEPN1-Related Myopathies: Mechanisms, Models, and Therapeutic Perspectives},
journal = {Biomolecules},
year = {2026},
doi = {10.3390/biom16010125}
}
EUVIMED